Tabata T - Search Results

1

Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.

Miki T, Nakatsuka K, Nishizawa Y, Emoto M, Morita A, Tabata T, Matsushita Y, Inoue T, Morii H. Miki T, et al. Among authors: tabata t. Endocrinol Jpn. 1991 Oct;38(5):479-83. doi: 10.1507/endocrj1954.38.479. Endocrinol Jpn. 1991. PMID: 1843267 Free article.

2

Effects of dietary phosphorus restriction on secondary hyperparathyroidism in hemodialysis patients during intermittent oral high-dose 1,25(OH)2D3 treatment.

Tabata T, Shoji S, Morita A, Emoto M, Inoue T, Miki T, Nishizawa Y, Morii H. Tabata T, et al. J Nutr Sci Vitaminol (Tokyo). 1991 Dec;37 Suppl:S105-12. doi: 10.3177/jnsv.37.supplement_s105. J Nutr Sci Vitaminol (Tokyo). 1991. PMID: 1820436

3

Circulating bone Gla protein in end-stage renal disease determined by newly developed two-site immunoradiometric assay.

Nakatsuka K, Miki T, Nishizawa Y, Tabata T, Inoue T, Morii H, Ogata E. Nakatsuka K, et al. Among authors: tabata t. Contrib Nephrol. 1991;90:147-54. doi: 10.1159/000420137. Contrib Nephrol. 1991. PMID: 1959340

4

In vivo effect of 1 alpha-hydroxyvitamin D3 on interleukin-2 production in hemodialysis patients.

Tabata T, Shoji T, Kikunami K, Matsushita Y, Inoue T, Tanaka S, Hino M, Miki T, Nishizawa Y, Morii H. Tabata T, et al. Nephron. 1988;50(4):295-8. doi: 10.1159/000185191. Nephron. 1988. PMID: 3266311

5

Growth of parathyroid gland in uremic patients on maintenance hemodialysis.

Kawagishi T, Nishizawa Y, Emoto M, Kawasaki K, Shoji S, Inaba M, Miki T, Morita A, Tabata T, Inoue T, et al. Kawagishi T, et al. Among authors: tabata t. Miner Electrolyte Metab. 1995;21(1-3):104-8. Miner Electrolyte Metab. 1995. PMID: 7565428

6

Influence of serum phosphate on the efficacy of oral 1,25-dihydroxyvitamin D3 pulse therapy.

Shoji S, Nishizawa Y, Tabata T, Emoto M, Morita A, Goto H, Ishimaura E, Inoue T, Inaba M, Miki T, et al. Shoji S, et al. Among authors: tabata t. Miner Electrolyte Metab. 1995;21(1-3):223-8. Miner Electrolyte Metab. 1995. PMID: 7565454

7

The effect of oral 1 alpha-hydroxycalciferol treatment on bone mineral density in hemodialysis patients.

Morita A, Tabata T, Inoue T, Nishizawa Y, Morii H. Morita A, et al. Among authors: tabata t. Clin Nephrol. 1996 Dec;46(6):389-93. Clin Nephrol. 1996. PMID: 8982555

8

Atherogenic lipoprotein changes in the absence of hyperlipidemia in patients with chronic renal failure treated by hemodialysis.

Shoji T, Nishizawa Y, Kawagishi T, Tanaka M, Kawasaki K, Tabata T, Inoue T, Morii H. Shoji T, et al. Among authors: tabata t. Atherosclerosis. 1997 Jun;131(2):229-36. doi: 10.1016/s0021-9150(97)00054-3. Atherosclerosis. 1997. PMID: 9199276

9

Plasma leptin level and its relationship with body composition in hemodialysis patients.

Nishizawa Y, Shoji T, Tanaka S, Yamashita M, Morita A, Emoto M, Tabata T, Inoue T, Morii H. Nishizawa Y, et al. Among authors: tabata t. Am J Kidney Dis. 1998 Apr;31(4):655-61. doi: 10.1053/ajkd.1998.v31.pm9531182. Am J Kidney Dis. 1998. PMID: 9531182

10

Changes in bone mineral density at various sites in patients on hemodialysis due to chronic glomerulonephritis.

Miki T, Morita A, Nakatsuka K, Tabata T, Inoue T, Nishizawa Y, Morii H. Miki T, et al. Among authors: tabata t. Osteoporos Int. 1997;7 Suppl 3:S193-6. doi: 10.1007/BF03194371. Osteoporos Int. 1997. PMID: 9536331 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,003 results

Search Page

Filters